| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Joslin Diabetes Center (P.A.E., E.T., E.S.H.) and Microcirculation Laboratory (A.C., L.K., A.V.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston Massachusetts 02215
Address all correspondence and requests for reprints to: Aristidis Veves, M.D., Microcirculation Laboratory, Palmer 317, Beth Israel Deaconess Medical Center, West Campus, One Deaconess Road, Boston, Massachusetts 02215. E-mail: aveves{at}bidmc.harvard.edu.
We have investigated the effect of atorvastatin on the endothelial function of patients with diabetes and subjects at risk for type 2 diabetes in a 12-wk, prospective, randomized, placebo-controlled, double-blind clinical trial. The flow- mediated dilation (FMD; endothelium dependent) and nitroglycerin-induced dilation (endothelium independent) in the brachial artery and the vascular reactivity at the forearm skin were measured. FMD improved in the atorvastatin-treated, at-risk subjects [median (25–75 percentile), 7.2% (2.9–9.6%) at exit visit vs. 6.6% (2.9–9.5%) at baseline; P < 0.05]. A similar improvement of FMD was found in atorvastatin-treated diabetic patients [median (25–75 percentile), 5.6 (3.9–7.9) at exit visit vs. 4.2 (3.2–7.2) at baseline; P = 0.07]. No changes were observed in nitroglycerin-induced dilation and the microcirculation reactivity measurements in either group. In the at-risk group, there was a decrease in the C-reactive protein [median (25–75 percentile), 0.12 mg/dl (0.07–0.27 mg/dl) at exit visit vs. 0.24 mg/dl (0.07–0.35 mg/dl) at baseline; P < 0.05] and TNF
[median (25–75 percentile), 2.6 pg/ml (1.8–4.1 pg/ml) at exit visit vs. 4.4 pg/ml (3.6–6.0 pg/ml) at baseline; P < 0.05] in the atorvastatin-treated patients, whereas in the diabetes group, a decrease in endothelin-1 (mean ± SD, 0.97 ± 0.29 pg/ml at exit visit vs. 1.19 ± 0.42 pg/ml at baseline; P < 0.05) and plasminogen activator inhibitor-1 [median (25–75 percentile), 18 ng/ml (9–24 ng/ml) at exit visit vs. 27 ng/ml (7–41 ng/ml) at baseline; P < 0.05] were observed. We conclude that atorvastatin improves endothelial function and decreases levels of markers of endothelial activation and inflammation.
This work was supported by a clinical research grant from Pfizer Inc. (to A.V.) and, in part, by Grant RR 01032 to the Beth Israel Deaconess Medical Center General Clinical Research Center from the National Institutes of Health, a William Randolph Hearst Fellowship provided by the William Randolph Hearst Foundation, and a Mary K. Iacocca Fellowship provided by the Iacocca Foundation.
Abbreviations: CRP, C-reactive protein; cv, coefficient of variation; FMD, flow-mediated dilation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAI, plasma activator inhibitor; tPA, tissue plasminogen activator.
This article has been cited by other articles:
 |
|
 |
|
  R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M S O'Neill, A Veves, J A Sarnat, A Zanobetti, D R Gold, P A Economides, E S Horton, and J Schwartz Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility Occup. Environ. Med., June 1, 2007; 64(6): 373 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kinlay Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Beckman, A. B. Goldfine, A. Dunaif, M. Gerhard-Herman, and M. A. Creager Endothelial Function Varies According to Insulin Resistance Disease Type Diabetes Care, May 1, 2007; 30(5): 1226 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T H Schindler, A D Facta, J O Prior, J Cadenas, W A Hsueh, M J Quinones, and H R Schelbert Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes Heart, March 1, 2007; 93(3): 345 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Lam, C.-H. Chu, M.-C. Wei, H.-M. Keng, C.-C. Lu, C.-C. Sun, J.-K. Lee, M.-J. Chuang, M.-C. Wang, and M.-H. Tai The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Experimental Biology and Medicine, June 1, 2006; 231(6): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 679 - 685.
|
|
|
|
|
|
E. D. Beishuizen, J. T. Tamsma, J. W. Jukema, M. A. van de Ree, J. C. M. van der Vijver, A. E. Meinders, and M. V. Huisman The Effect of Statin Therapy on Endothelial Function in Type 2 Diabetes Without Manifest Cardiovascular Disease Diabetes Care, July 1, 2005; 28(7): 1668 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. O'Neill, A. Veves, A. Zanobetti, J. A. Sarnat, D. R. Gold, P. A. Economides, E. S. Horton, and J. Schwartz Diabetes Enhances Vulnerability to Particulate Air Pollution-Associated Impairment in Vascular Reactivity and Endothelial Function Circulation, June 7, 2005; 111(22): 2913 - 2920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Shetty, P. A. Economides, E. S. Horton, C. S. Mantzoros, and A. Veves Circulating Adiponectin and Resistin Levels in Relation to Metabolic Factors, Inflammatory Markers, and Vascular Reactivity in Diabetic Patients and Subjects at Risk for Diabetes Diabetes Care, October 1, 2004; 27(10): 2450 - 2457. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
